GSK plc (NYSE:GSK) Shares Bought by Voloridge Investment Management LLC

Voloridge Investment Management LLC grew its position in GSK plc (NYSE:GSK) by 1,360.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,165,043 shares of the pharmaceutical company’s stock after acquiring an additional 2,016,795 shares during the period. Voloridge Investment Management LLC’s holdings in GSK were worth $73,222,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GSK. Dorsey & Whitney Trust CO LLC raised its holdings in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after purchasing an additional 278 shares during the period. GC Wealth Management RIA LLC increased its position in shares of GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after buying an additional 353 shares in the last quarter. Jacobi Capital Management LLC raised its stake in shares of GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after buying an additional 389 shares during the period. Gladstone Institutional Advisory LLC lifted its position in shares of GSK by 3.4% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company’s stock valued at $413,000 after buying an additional 407 shares in the last quarter. Finally, CENTRAL TRUST Co grew its stake in GSK by 5.6% in the 4th quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company’s stock valued at $262,000 after acquiring an additional 414 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a research report on Monday, April 28th. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. BNP Paribas assumed coverage on GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price objective on the stock. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 24th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.58.

GSK Stock Performance

GSK opened at $38.38 on Wednesday. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.80. The firm has a market capitalization of $79.19 billion, a PE ratio of 24.14, a PEG ratio of 1.12 and a beta of 0.51. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The firm’s 50-day moving average price is $37.35 and its 200 day moving average price is $35.98.

GSK (NYSE:GSK) last released its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $0.43 EPS. As a group, sell-side analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.39%. GSK’s dividend payout ratio (DPR) is presently 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.